Browsing Tag
Crinetics Pharmaceuticals
3 posts
Vertex just completed a $10bn acquisition. Why is Jonathan Poole becoming CFO now?
Vertex Pharmaceuticals has split the operating and finance responsibilities held by Charles Wagner as it begins integrating the $10 billion Crinetics Pharmaceuticals acquisition and targets more than $5 billion of potential peak sales from its new endocrine assets.
Vertex (VRTX) to enter endocrine diseases with $10bn Crinetics acquisition, targets $5bn peak revenue by 2029
Vertex Pharmaceuticals to acquire Crinetics for $10 billion at 102% premium, largest deal in VRTX history. Read the full analysis.
Crinetics Pharmaceuticals shares soar after FDA clears Palsonify, the first oral acromegaly treatment
Crinetics shares surged after FDA approval of Palsonify, the first oral acromegaly therapy. Learn how this launch reshapes patient care and investor sentiment.